A reader was excited about this and asked if I would post this research related press release from the MMRF:
The Multiple Myeloma Research Foundation (MMRF) and Leukemia & Lymphoma Society (LLS) Partner to Fund $500,000 in Cancer Stem Cell Research Grants
Norwalk, CT and White Plains, NY — February 16, 2009
The Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS) have partnered to award William Matsui, MD, Johns Hopkins University, and Irving Weissman, MD, Stanford University, research grants totaling $500,000 to study the multiple myeloma cancer stem cell. Each individual grant is valued at $250,000
These grants, developed in response to input from leading cancer stem cell experts who participated in the 2008 MMRF Myeloma Cancer Stem Cell Research Roundtable, provide an unprecedented opportunity to apply existing knowledge of cancer stem cells to multiple myeloma. Ultimately, the identification and characterization of the multiple myeloma cancer stem cell will advance our understanding of drug resistance and relapse in patients with multiple myeloma and potentially lead to the development of targeted therapies that effectively treat the disease.
“The emerging field of cancer stem cell research holds enormous promise for patients—particularly those with an orphan disease, such as multiple myeloma, for which effective treatments remain limited” said Louise Perkins, PhD, Chief Scientific Officer of the MMRF. “The MMRF is pleased to partner with LLS to advance this important research effort and lay the groundwork for the development of better, more effective treatments.”
Many researchers believe that cancer stem cells, although few in number, are responsible for cancer’s development, metastases, and recurrence.
“By putting our resources together, LLS and MMRF have identified some of the most promising researchers in the field of stem cell biology as it relates to myeloma,” said John Walter, President and Chief Executive Officer of LLS. “Ultimately, the identification and characterization of cancer stem cells in myeloma may enable the development of more effective therapies.”
Targeted research grants like these are a cost-efficient way to approach a specific challenge like unlocking the potential of therapeutic stem cells. Great to see the MMRF and LLS working together! Thanks, Anne!
Feel good and keep smiling! Pat